COVID-19 vaccination in India
http://dbpedia.org/resource/COVID-19_vaccination_in_India
La vacunación contra la COVID-19 en la India es la estrategia nacional de vacunación que está en curso desde el 16 de enero de 2021 para inmunizar a la población contra la COVID-19 en el territorio, en el marco de un esfuerzo mundial para combatir la pandemia de COVID-19. En un inicio, el operativo estimaba utilizar 600 millones de dosis, para vacunar a 300 millones de personas según su ocupación o grupo etario, y se estima que este se complete en un período de seis meses, hasta agosto de 2021.
rdf:langString
Vaksinasi Covid-19 di India mulai diadakan pada 16 Januari 2021. Pada 23 Desember 2021, India memberikan lebih dari 1.39 miliar dosis secara keseluruhan, termasuk dosis pertama dan kedua dari vaksin yang kini disepakati. Di India, 80% populasi layak menerima setidaknya satu suntikan, dan jumlah vaksinasi penuh melampaui jumlah orang yang disuntik sebagian. India awalnya menyepakati vaksin Oxford–AstraZeneca (diproduksi di bawah lisensi oleh Serum Institute of India dengan nama dagang Covishield) dan Covaxin (sebuah vaksin yang dikembangkan secara lokal oleh Bharat Biotech).
rdf:langString
인도의 코로나19 예방접종은 코로나19에 대응하기 위한 인도에서의 백신접종 프로그램이다. 현재 인도에서는 아스트라제네카, 코백신, 스푸트니크V 이렇게 3개 백신이 사용 중이고, 허가되었지만 사용되지 않는 백신으로는 모더나와 ZyCoV-D, 그리고 얀센이 있다.
rdf:langString
India began administration of COVID-19 vaccines on 16 January 2021. As of 2 December 2022, India has administered over 2.19 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated. According to a June 2022 study published in The Lancet, COVID-19 vaccination in India prevented an additional 4.2 million deaths from December 8, 2020, to December 8, 2021.
rdf:langString
rdf:langString
COVID-19 vaccination in India
rdf:langString
Vacunación contra la COVID-19 en India
rdf:langString
Vaksinasi Covid-19 di India
rdf:langString
인도의 코로나19 예방접종
xsd:integer
66402396
xsd:integer
1119449326
rdf:langString
State governments of India
rdf:langString
* ' of the Indian population has received one dose.
* ' of the Indian population has received both doses
rdf:langString
center
rdf:langString
Source: CoWin Dashboard
xsd:gMonthDay
--01-22
rdf:langString
A vial of Covishield, the Indian-manufactured version of the AstraZeneca vaccine.
rdf:langString
A vial of Covaxin
rdf:langString
wikitable
xsd:integer
163815894
xsd:integer
943134383
xsd:integer
1023156959
xsd:date
2021-01-16
rdf:langString
vertical
rdf:langString
Bharat Biotech Covaxin Bangalore BESTpedia.jpg
rdf:langString
Covishield K .jpg
rdf:langString
Fully Vaccinated
rdf:langString
Partially Vaccinated
rdf:langString
Precautionary Dose
rdf:langString
India
xsd:gMonthDay
--08-01
rdf:langString
* 1,019,762,144 people with one dose administered of Covaxin or Oxford–AstraZeneca vaccine or Sputnik V
* 932,986,319 people have been fully vaccinated with both doses of Covaxin or Oxford–AstraZeneca vaccine or Sputnik V or Corbevax
* 9,06,55,213 people have been administered Precautionary/Booster doses of Covaxin or Oxford–AstraZeneca vaccine or Sputnik V or Corbevax
rdf:langString
Government — 1,10,000
rdf:langString
Private — 2,700
rdf:langString
Immunisation of Indians against COVID-19
xsd:integer
50
rdf:langString
COVID-19 vaccination programme
rdf:langString
Sites conducting vaccination in India
xsd:integer
100
xsd:integer
1013016000
rdf:langString
Vaccination
rdf:langString
Dose
rdf:langString
India began administration of COVID-19 vaccines on 16 January 2021. As of 2 December 2022, India has administered over 2.19 billion doses overall, including first, second and precautionary (booster) doses of the currently approved vaccines. In India, 95% of the eligible population (12+) has received at least one shot, and 88% of the eligible population (12+) is fully vaccinated. India initially approved the Oxford–AstraZeneca vaccine (manufactured under license by Serum Institute of India under the trade name Covishield) and Covaxin (a vaccine developed locally by Bharat Biotech). They have since been joined by the Sputnik V (manufactured under license by Dr. Reddy's Laboratories, with additional production from Serum Institute of India being started in September), Moderna vaccines, Johnson & Johnson vaccine and ZyCoV-D (a vaccine locally developed by Zydus Cadila) and other vaccine candidates undergoing local clinical trials. According to a June 2022 study published in The Lancet, COVID-19 vaccination in India prevented an additional 4.2 million deaths from December 8, 2020, to December 8, 2021.
rdf:langString
La vacunación contra la COVID-19 en la India es la estrategia nacional de vacunación que está en curso desde el 16 de enero de 2021 para inmunizar a la población contra la COVID-19 en el territorio, en el marco de un esfuerzo mundial para combatir la pandemia de COVID-19. En un inicio, el operativo estimaba utilizar 600 millones de dosis, para vacunar a 300 millones de personas según su ocupación o grupo etario, y se estima que este se complete en un período de seis meses, hasta agosto de 2021.
rdf:langString
Vaksinasi Covid-19 di India mulai diadakan pada 16 Januari 2021. Pada 23 Desember 2021, India memberikan lebih dari 1.39 miliar dosis secara keseluruhan, termasuk dosis pertama dan kedua dari vaksin yang kini disepakati. Di India, 80% populasi layak menerima setidaknya satu suntikan, dan jumlah vaksinasi penuh melampaui jumlah orang yang disuntik sebagian. India awalnya menyepakati vaksin Oxford–AstraZeneca (diproduksi di bawah lisensi oleh Serum Institute of India dengan nama dagang Covishield) dan Covaxin (sebuah vaksin yang dikembangkan secara lokal oleh Bharat Biotech).
rdf:langString
인도의 코로나19 예방접종은 코로나19에 대응하기 위한 인도에서의 백신접종 프로그램이다. 현재 인도에서는 아스트라제네카, 코백신, 스푸트니크V 이렇게 3개 백신이 사용 중이고, 허가되었지만 사용되지 않는 백신으로는 모더나와 ZyCoV-D, 그리고 얀센이 있다.
xsd:double
86.98999999999999
xsd:double
94.37
xsd:nonNegativeInteger
137077
